Journal Article

Progressive supranuclear palsy (PSP) is a fatal 4-repeat (4R) tauopathy with progressive movement phenotypes. In-vivo 4R tau biomarkers are therefore crucial for PSP diagnosis, monitoring, and treatment evaluation. [...]

A recent retrospective analysis of Enroll HD data suggesting β-blockers slow Huntington's disease progression has triggered patient demand but requires caution. The findings rely solely on small observational subsets and are vulnerable to bias and confounding. [...]

Parkinson's disease (PD) exhibits high heterogeneity in disease progression, complicating management and increasing required sample sizes for clinical trials. This study evaluates Brain Age Gap (BAG)-the difference between brain age and chronological age-for predicting disease progression in PD. [...]

Normative data of neuropsychological tests in the Vietnamese population is considerably lacking. We aim to evaluate the effects of age, education, and sex on the performance of common neuropsychological tests, and to generate normative data for these tests in cognitively normal Vietnamese adults.Participants were recruited from two hospitals in Ho Chi Minh City, with inclusion criteria as follows: age ≥ 40 years, normal cognition and function, and Mini-Mental State Examination (MMSE) scores ≥ 26. [...]

Progressive supranuclear palsy (PSP) is a primary tauopathy characterized by atrophy and neuroinflammation of the brainstem, the basal ganglia and, to a lesser degree, the cortex. This study investigates the association of regional atrophy (structural MRI), neuroinflammation ([11C]-PK11195 PET), peripheral markers of neurodegeneration [plasma neurofilament light chain (NfL)] and clinical severity [PSP rating scale (PSPRS)] with survival in people with PSP. [...]